Market Place
Sourcing Support
Gradalis Develops Exome Sequencing Pipeline for Tumor Mutation
14 Mar 2025 //
GLOBENEWSWIRE
Gradalis Secures FDA RMAT for Vigil Immunotherapy in Ovarian Cancer
05 Feb 2025 //
GLOBENEWSWIRE
GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on KRAS Mutations
04 Jan 2024 //
GLOBENEWSWIRE
Gradalis Highlights Importance of Clonal Neoantigens in Achieving Benefit in Cancer Treatment
05 Dec 2023 //
GLOBENEWSWIRE
Gradalis Awarded $9.9 Million Grant From the Research Institute of Texas
16 Nov 2023 //
GLOBENEWSWIRE
Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2
18 Oct 2023 //
GLOBENEWSWIRE
Gradalis Highlights Importance of Clonal Neoantigen Targeting Benefit of Vigil
28 Sep 2023 //
GLOBENEWSWIRE
Gradalis to Participate in the Cantor Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Solve & Gradalis Sign Agreement to Develop a Novel Gene Therapy Targeting HIBM
31 Jul 2023 //
GLOBENEWSWIRE
Gradalis Announces highlights Potential of Novel 3D Scaffold Tissue Technology
06 Jun 2023 //
GLOBENEWSWIRE
Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
29 Mar 2023 //
GLOBENEWSWIRE
Gradalis to Present at the 2023 BIO CEO & Investor Conference
02 Feb 2023 //
GLOBENEWSWIRE
US FDA grants approval for Gradalis’ Phase III ovarian cancer trial
23 Dec 2022 //
CLINICALTRIALSARENA
Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil
21 Dec 2022 //
PRNEWSWIRE
Gradalis Appoints Eric Hall as Chief Financial Officer
14 Dec 2022 //
GLOBENEWSWIRE
Gradalis to Present at the 2022 Cell & Gene Meeting on the Mesa
04 Oct 2022 //
GLOBENEWSWIRE
Gradalis to Host Key Opinion Leader Webinar on Unmet Medical in Ovarian Cancer
28 Sep 2022 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.